drugset / Trial / NCT05166876
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
RandomizedParallel-groupTriple-blindTreatment
Summary
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2022-06-04
- Completion
- 2022-06-04
Outcome
Outcome not reported
Stopped: “Low prevalence of COVID-19 in India led to lack of eligible subjects.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brequinar | Small molecule | 50 mg | Oral |
| Subject | Brequinar | Small molecule | 100 mg | Oral |
| Subject | Brequinar | Small molecule | 150 mg | Oral |
| Subject | Brequinar | Small molecule | 200 mg | Oral |
| Subject | Dipyridamole | Other / unclassified | 75 mg | Oral |